4523.T
Eisai Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 4,811.00
+1.67%Sep 3, 2026, 04:00 UTC
Eisai announced that China approved LEQEMBI (lecanemab) subcutaneous formulation as an initiation treatment for early Alzheimer's disease, enabling at-home administration.
Aug 31, 2026, 23:30 UTC
Canada's Drug Agency issued a final positive recommendation supporting public reimbursement of Eisai's LEQEMBI (lecanemab) for early Alzheimer's disease.
Source:Aug 28, 2026, 00:18 UTC
China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.
Source:Aug 26, 2026, 09:31 UTC
Japan's Ministry of Health, Labour and Welfare expert panel deliberated on approval of Eisai and Biogen's Alzheimer's drug Leqembi subcutaneous injection formulation, which would allow home administration.
Source:Aug 24, 2026, 12:00 UTC
Eisai announced that the LEQEMBI IQLIK (lecanemab-irmb) autoinjector for initiation of therapy is now available in the U.S. for early Alzheimer's disease.
Aug 3, 2026, 15:55 UTC
Eisai launched Leqembi (lecanemab) for early Alzheimer's disease in India, priced at ₹21,682 per vial.
Source: